Details of the Drug

General Information of Drug (ID: DMSLQW2)

Drug Name
TRPH-222
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
DQC80I
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease B-cell lymphoma
ICD Disease Classification 2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03682796) Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Triphase Accelerator.